The Challenge of Finding a Cure for HIV Infection

被引：690

作者：

Richman, Douglas D. ^{[1
]}

Margolis, David M. ^{[2
]}

Delaney, Martin ^{[3
]}

Greene, Warner C. ^{[4
]}

Hazuda, Daria ^{[5
]}

Pomerantz, Roger J. ^{[6
,7
]}

机构：

[1] San Diego VA Healthcare Syst, La Jolla, CA 92093 USA

[2] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA

[3] Project Inform, San Francisco, CA 94103 USA

[4] Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA

[5] Merck & Co Inc, West Point, PA 19486 USA

[6] Johnson & Johnson Corp, Yardley, PA 19067 USA

[7] Tibotec Pharmaceut Inc, Yardley, PA 19067 USA

来源：

SCIENCE | 2009年 / 323卷 / 5919期

关键词：

HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; REPLICATION-COMPETENT HIV; CENTRAL-NERVOUS-SYSTEM; NF-KAPPA-B; CELLULAR RESERVOIRS; ANTIVIRAL THERAPY; P-TEFB; LATENCY;

D O I：

10.1126/science.1165706

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Although combination therapy for HIV infection represents a triumph for modern medicine, chronic suppressive therapy is required to contain persistent infection in reservoirs such as latently infected CD4(+) lymphocytes and cells of the macrophage-monocyte lineage. Despite its success, chronic suppressive therapy is limited by its cost, the requirement of lifelong adherence, and the unknown effects of long-term treatment. This review discusses our current understanding of suppressive antiretroviral therapy, the latent viral reservoir, and the needs for and challenges of attacking this reservoir to achieve a cure.

引用

页码：1304 / 1307

页数：4

共 48 条

[1]

[Anonymous], 2008, UN ACC SCAL PRIOR HI

[2] Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells [J].

Archin, Nancy M. ;

Eron, Joseph J. ;

Palmer, Sarah ;

Hartmann-Duff, Anne ;

Martinson, Jeffery A. ;

Wiegand, Ann ;

Bandarenko, Nicholas ;

Schmitz, John L. ;

Bosch, Ronald J. ;

Landay, Alan L. ;

Coffin, John M. ;

Margolis, David M. .

AIDS, 2008, 22 (10) :1131-1135

[3] Residual human immunodeficiency virus type 1 viremia in some patients on Antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells [J].

Bailey, JR ;

Sedaghat, AR ;

Kieffer, T ;

Brennan, T ;

Lee, PK ;

Wind-Rotolo, M ;

Haggerty, CM ;

Kamireddi, AR ;

Liu, Y ;

Lee, J ;

Persaud, D ;

Gallant, JE ;

Cofrancesco, J ;

Quinn, TC ;

Wilke, CO ;

Ray, SC ;

Siliciano, JD ;

Nettles, RE ;

Siliciano, RF .

JOURNAL OF VIROLOGY, 2006, 80 (13) :6441-6457

[4] Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era [J].

Bedimo R. .

Current HIV/AIDS Reports, 2008, 5 (3) :140-149

[5]

Bisgrove Dwayne, 2005, Expert Rev Anti Infect Ther, V3, P805, DOI 10.1586/14787210.3.5.805

[6] Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4+ T cells [J].

Choudhary, Shailesh K. ;

Archin, Nancy M. ;

Margolis, David M. .

JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (08) :1162-1170

[7] Quantification of latent tissue reservoirs and total body viral load in HIV-1 Infection [J].

Chun, TW ;

Carruth, L ;

Finzi, D ;

Shen, XF ;

DiGiuseppe, JA ;

Taylor, H ;

Hermankova, M ;

Chadwick, K ;

Margolick, J ;

Quinn, TC ;

Kuo, YH ;

Brookmeyer, R ;

Zeiger, MA ;

BarditchCrovo, P ;

Siliciano, RF .

NATURE, 1997, 387 (6629) :183-188

[8] Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy [J].

Chun, TW ;

Engel, D ;

Mizell, SB ;

Hallahan, CW ;

Fischette, M ;

Park, S ;

Davey, RT ;

Dybul, M ;

Kovacs, JA ;

Metcalf, JA ;

Mican, JM ;

Berrey, MM ;

Corey, L ;

Lane, HC ;

Fauci, AS .

NATURE MEDICINE, 1999, 5 (06) :651-655

[9] HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription [J].

Contreras, Xavier ;

Barboric, Matjaz ;

Lenasi, Tina ;

Peterlin, B. Matija .

PLOS PATHOGENS, 2007, 3 (10) :1459-1469

[10] The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1 [J].

Coull, JJ ;

Romerio, F ;

Sun, JM ;

Volker, JL ;

Galvin, KM ;

Davie, JR ;

Shi, Y ;

Hansen, U ;

Margolis, DM .

JOURNAL OF VIROLOGY, 2000, 74 (15) :6790-6799

← 1 2 3 4 5 →